Suppr超能文献

地塞米松治疗全身性糖皮质激素抵抗所致同性性早熟假性青春期。

Dexamethasone therapy for isosexual precocious pseudopuberty caused by generalized glucocorticoid resistance.

作者信息

Malchoff C D, Reardon G, Javier E C, Rogol A D, McDermott P, Loriaux D L, Malchoff D M

机构信息

Department of Surgery, University of Connecticut Health Center, Farmington 06030-1110.

出版信息

J Clin Endocrinol Metab. 1994 Dec;79(6):1632-6. doi: 10.1210/jcem.79.6.7989467.

Abstract

Generalized glucocorticoid resistance presents with clinical features secondary to excess production of mineralocorticoids and adrenal androgens. It is our hypothesis that these clinical and biochemical features will respond to glucocorticoid therapy. We tested this hypothesis in a boy with generalized glucocorticoid resistance and increased adrenal androgens. Dexamethasone was administered from age 7 6/12 yr until the onset of true puberty at 11 0/12 yr. Serum concentrations of cortisol and adrenal androgens decreased to the normal or near normal range. The accelerated precocity improved. Secondary sex characteristics did not progress; the difference between bone age and chronological age decreased from 3 1/2 yr to 2 yr, and the difference between height age and bone age decreased from 2 yr to 1/2 yr. We conclude that dexamethasone is effective and safe therapy for the sexual precocity of generalized glucocorticoid resistance.

摘要

全身性糖皮质激素抵抗表现为继发于盐皮质激素和肾上腺雄激素过量产生的临床特征。我们的假设是,这些临床和生化特征对糖皮质激素治疗会有反应。我们在一名患有全身性糖皮质激素抵抗且肾上腺雄激素增加的男孩中检验了这一假设。地塞米松从7岁6/12岁开始给药,直至11岁0/12岁进入真性青春期。血清皮质醇和肾上腺雄激素浓度降至正常或接近正常范围。加速性早熟得到改善。第二性征未进展;骨龄与实际年龄的差异从3.5岁降至2岁,身高年龄与骨龄的差异从2岁降至0.5岁。我们得出结论,地塞米松是治疗全身性糖皮质激素抵抗性性早熟的有效且安全的疗法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验